ABIOMED (NASDAQ:ABMD) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

ABMD has been the subject of several other research reports. Zacks Investment Research upgraded ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price target for the company in a report on Monday, October 30th. SunTrust Banks restated a “buy” rating and set a $195.00 price target on shares of ABIOMED in a report on Wednesday, November 1st. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price target on shares of ABIOMED in a report on Tuesday, August 29th. Jefferies Group raised their price target on ABIOMED from $175.00 to $208.00 and gave the company a “buy” rating in a report on Friday, September 29th. Finally, Leerink Swann restated an “outperform” rating and set a $200.00 price target (up previously from $180.00) on shares of ABIOMED in a report on Thursday, October 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. ABIOMED currently has an average rating of “Buy” and an average price target of $190.43.

Shares of ABIOMED (NASDAQ ABMD) traded up $0.27 on Tuesday, reaching $188.71. The company had a trading volume of 367,842 shares, compared to its average volume of 332,526. The company has a market cap of $8,340.00, a P/E ratio of 120.97, a PEG ratio of 2.51 and a beta of 0.15. ABIOMED has a 52 week low of $103.53 and a 52 week high of $200.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.16. The company had revenue of $132.80 million for the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter last year, the company earned $0.20 EPS. equities research analysts predict that ABIOMED will post 2.38 EPS for the current year.

In other news, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the completion of the transaction, the director now owns 39,532 shares in the company, valued at approximately $7,079,390.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Andrew J. Greenfield sold 11,282 shares of ABIOMED stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $169.32, for a total value of $1,910,268.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,646 shares of company stock valued at $4,836,333. Company insiders own 7.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Seven Eight Capital LP purchased a new position in ABIOMED during the 2nd quarter valued at $100,000. Rehmann Capital Advisory Group purchased a new position in ABIOMED during the 3rd quarter valued at $202,000. Sigma Planning Corp purchased a new position in ABIOMED during the 3rd quarter valued at $206,000. Dorsey & Whitney Trust CO LLC purchased a new position in ABIOMED during the 3rd quarter valued at $215,000. Finally, First Allied Advisory Services Inc. purchased a new position in ABIOMED during the 3rd quarter valued at $234,000. Hedge funds and other institutional investors own 90.92% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ABIOMED (ABMD) Downgraded by BidaskClub to “Hold”” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/17/abiomed-abmd-downgraded-by-bidaskclub-to-hold.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.